- Press releases

Asceneuron appoints Peter Van Vlasselaer as Chairman

Asceneuron appoints Peter Van Vlasselaer as Chairman

- News

Interview of Dirk Beher, CEO & Founder, at the Biotech Showcase

Dirk Beher, CEO & Founder, was interviewed by Mike Ward (Scrip Pharma Intelligence) at the Biotech Showcase in San Francisco last week.

- Event

Asceneuron to attend the 37th Annual J.P. Morgan Healthcare Conference

Asceneuron will be taking meetings around the 37th Annual J.P. Morgan Healthcare Conference held on January 7-10, 2018 in San Francisco, CA.

- Press releases

Asceneuron appoints Dr. Thomas C. Wessel as Chief Medical Officer

Asceneuron appoints Dr. Thomas C. Wessel as Chief Medical Officer

- Press releases

Asceneuron initiates neuroimaging trial for ASN120290

Asceneuron initiates neuroimaging trial for tau modifier ASN120290

- Event

Asceneuron panelist at BIO-Europe 2018

Asceneuron will take part to a panel discussion at BIO-Europe, on November 5th-7th, 2018 in Copenhagen, Denmark.

- Press releases

ASN120290 receives Orphan Drug Designation from the FDA

Asceneuron’s tau modifier ASN120290 receives Orphan Drug Designation for progressive supranuclear palsy from the FDA

- Event

Asceneuron to present at the European Life Sciences CEO Forum

Our CEO Dirk Beher will be presenter and panellist at the 11th Annual European Life Sciences CEO Forum & Exhibition, February 26th-27th 2018, in Zurich.

- Event

Asceneuron to attend the 36th Annual J.P. Morgan Healthcare Conference

Asceneuron to attend the 36th Annual J.P. Morgan Healthcare Conference taking place January 8-11, 2018 at the Westin St. Francis in San Francisco, CA.

- Event

Asceneuron to present at Neurotech Investing and Partnering Conference

Our CEO Dirk Beher will be presenter and panellist at Neurotech Investing and Partnering Conference, October 3rd 2017, in Geneva.